{"id":"NCT03461289","sponsor":"Novartis Gene Therapies","briefTitle":"Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1","officialTitle":"Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-16","primaryCompletion":"2020-09-11","completion":"2020-09-11","firstPosted":"2018-03-12","resultsPosted":"2021-04-02","lastUpdate":"2022-08-16"},"enrollment":33,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["SMA"],"interventions":[{"type":"BIOLOGICAL","name":"Onasemnogene Abeparvovec-xioi","otherNames":["AVXS-101","OAV101","Zolgensma"]}],"arms":[{"label":"Onasemnogene Abeparvovec-xioi","type":"EXPERIMENTAL"}],"summary":"Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 gene (SMN1) with one or two copies of survival motor neuron 2 gene (SMN2). Up to 30 patients \\< 6 months (\\< 180 days) of age at the time of gene replacement therapy (Day 1) will be enrolled.","primaryOutcome":{"measure":"Number of Participants Who Achieve Independent Sitting for at Least 10 Seconds","timeFrame":"From Day 1 up to 18 Months of Age Visit (Up to a Maximum of Approximately 17 Months)","effectByArm":[{"arm":"Onasemnogene Abeparvovec-xioi","deltaMin":14,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":10,"countries":["Belgium","France","Italy","United Kingdom"]},"refs":{"pmids":["34536405","34383289"],"seeAlso":["https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17805"]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":33},"commonTop":["Pyrexia","Upper respiratory tract infection","Alanine aminotransferase increased","Aspartate aminotransferase increased","Vomiting"]}}